In an age of new therapies, a key question facing doctors and patients alike is when you’ll know you are diagnosed with a specific cancer or cancer treatment.
This week, the Institute of Medicine released a landmark report that offers some answers.
The study was the first to examine how the human immune system reacts to new and potentially deadly diseases, as well as the impact on survival rates and cancer patients’ ability to make decisions about their own care.
The results have opened up new avenues for cancer researchers, researchers and patients to learn more about the immune system and how it responds to threats, including new cancers.
The institute says that its findings, which were published in the American Journal of Cancer, were based on research in mice, rats and human beings.
Here’s what you need to know: What is the IOM’s report?
The IOM is a U.S.-based organization that provides advice on health and medicine to the federal government, the private sector, and academia.
The I, and the I, are an independent scientific organization whose mission is to develop evidence-based medicine and advance public health.
Its study is the first comprehensive review of the immune response to new diseases.
The report was published on Monday, and is available online at the institute’s website, as is the full report.
The first part of the report focuses on immune system responses to the human body’s most common and most dangerous pathogens, which include influenza, coronavirus, anthrax and herpes.
It also looks at the response of the human gut to pathogens and cancer.
This part of what the I-O is about is the role of the intestinal immune system, which plays a role in maintaining intestinal health, as the researchers say.
The second part of their report looks at how different types of cancers and other cancers respond to immune-system therapies.
The last part of this report examines the impact of treatment on survival, and it examines the role the immune-mediated immune response plays in disease progression and treatment outcomes.
How did the IO get the data?
Researchers used mice to mimic the human inflammatory response.
This type of research is considered a basic science and can be done in a laboratory or by studying mice, but it can also be done using a mouse model in humans.
This study was funded by the National Institutes of Health and the National Cancer Institute.
The Institute of Science Education and Research, a program of the National Science Foundation, was also a sponsor of the study.
How does the research look?
The researchers studied mice that received either chemotherapy or non-therapy immune-stimulating therapies.
This was done to simulate the immune responses of human patients.
The researchers compared the mice’ immune systems to the immune systems of mice that had received chemotherapy.
The mice had a reduced response to chemotherapy and the mice that did not received chemotherapy were not significantly different from the mice receiving non-treatment therapies.
In addition, when researchers used the mice to receive either chemotherapy and/or non-toxic immunotherapy therapies, the mice with the reduced response were less aggressive than the mice who did not receive the treatments.
The authors say this finding could have important implications for cancer research.
The same researchers who studied mice also used other types of animal models and used humans as models to study the immune activity of the people who are undergoing the treatment.
What did they find?
The scientists found that, in addition to the reduction in aggressive behavior, the immune cells of mice treated with chemotherapy responded to the treatment by increasing the levels of antibodies, a type of immune molecule that fights cancer cells.
The immunotherapy therapy was also able to inhibit tumor growth, and thus reduce cancer in the mice.
This suggests that treatment with the immune stimulants might be effective in treating cancer in humans, says the IOP, as this type of treatment might be helpful for patients who do not respond to the immunotherapy.
How do researchers interpret the findings?
In their study, the researchers found that the immune stimulus, which they called the “immune-stimulated response,” decreased in response to the chemotherapy.
This could indicate that the mice were responding to the chemo by increasing their immune responses, but also that the treatment could also be affecting their behavior by reducing aggressive behavior.
These findings support the hypothesis that chemo can influence the immune program, says Dr. Thomas T. Hahn, the director of the Institute for Regenerative Medicine at the Icahn School of Medicine at Mount Sinai in New York City.
He notes that previous research has shown that chemotactic therapies can cause some mice to have a reduced immune response, but he also notes that there is much more work to be done to confirm this hypothesis.
How can people know if they have a specific type of cancer?
The institute’s study found that mice treated either with chemotherapy or with non-coating immune-suppressing agents showed a reduced inflammatory response compared to mice not treated with chemo or with no treatments.
However, the institute said the mice also had an increased tumor response compared with mice